Literature DB >> 29874526

Encouraging Trends in Modern Phase 1 Oncology Trials.

Camille Chakiba1, Thomas Grellety1, Carine Bellera1, Antoine Italiano1.   

Abstract

Mesh：

Year:  2018        PMID： 29874526     DOI： 10.1056/NEJMc1803837

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  18 in total

1.  Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era.

Authors:  Tira Tan; Michael Rheaume; Lisa Wang; Helen Chow; Anna Spreafico; Aaron R Hansen; Albiruni R A Razak; Lillian L Siu; Philippe L Bedard
Journal:  Oncologist       Date:  2019-03-04

2.  Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials.

Authors:  Dai Chihara; Ruitao Lin; Christopher R Flowers; Shanda R Finnigan; Lisa M Cordes; Yoko Fukuda; Erich P Huang; Larry V Rubinstein; Loretta J Nastoupil; S Percy Ivy; James H Doroshow; Naoko Takebe
Journal:  Lancet       Date:  2022-08-13       Impact factor: 202.731

3.  Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute.

Authors:  Dai Chihara; Erich P Huang; Shanda R Finnigan; Lisa M Cordes; Nebojsa Skorupan; Yoko Fukuda; Larry V Rubinstein; S Percy Ivy; James H Doroshow; Loretta J Nastoupil; Christopher R Flowers; Naoko Takebe
Journal:  J Clin Oncol       Date:  2022-03-09       Impact factor: 50.717

4.  A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study.

Authors:  Sarah A Buckley; Mary-Elizabeth Percival; Megan Othus; Anna B Halpern; Emily M Huebner; Pamela S Becker; Carole Shaw; Mazyar Shadman; Roland B Walter; Elihu H Estey
Journal:  Leuk Lymphoma       Date:  2018-10-02

5.  Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials.

Authors:  Carmen Criscitiello; Antonio Marra; Stefania Morganti; Paola Zagami; Giulia Viale; Angela Esposito; Giuseppe Curigliano
Journal:  Oncologist       Date:  2020-09-18

6.  Improved survival among patients enrolled in oncology phase 1 trials in recent decades.

Authors:  Takahiro Ebata; Toshio Shimizu; Takafumi Koyama; Akihiko Shimomura; Satoru Iwasa; Shunsuke Kondo; Shigehisa Kitano; Kan Yonemori; Yutaka Fujiwara; Noboru Yamamoto
Journal:  Cancer Chemother Pharmacol       Date:  2019-11-19       Impact factor: 3.333

Review 7.  Phase I trials as valid therapeutic options for patients with cancer.

Authors:  Jacob J Adashek; Patricia M LoRusso; David S Hong; Razelle Kurzrock
Journal:  Nat Rev Clin Oncol       Date:  2019-09-02       Impact factor: 66.675

Review 8.  Opportunities and Challenges in Drug Development for Pediatric Cancers.

Authors:  Theodore W Laetsch; Steven G DuBois; Julia Glade Bender; Margaret E Macy; Lucas Moreno
Journal:  Cancer Discov       Date:  2020-12-04       Impact factor: 38.272

9.  Conducting Phase I Trials During the SARS-Coronavirus-2 Outbreak: About Science and Care.

Authors:  Angelo Dipasquale; Pasquale Persico; Elena Lorenzi; Monica Bertossi; Armando Santoro; Matteo Simonelli
Journal:  Front Oncol       Date:  2020-05-22       Impact factor: 6.244

10.  A randomized controlled trial of structured palliative care versus standard supportive care for patients enrolled in phase 1 clinical trials.

Authors:  Michelle Treasure; Barbara Daly; Shufen Cao; Pingfu Fu; Augustine Hong; Elizabeth Weinstein; Jessica Surdam; Neal J Meropol; Afshin Dowlati
Journal:  Cancer Med       Date:  2021-05-25       Impact factor: 4.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.